High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load

Tseng, Tai‐Chung; Liu, Chun‐Jen; Yang, Hung‐Chih; Su, Tung‐Hung; Wang, Chia–Chi; Chen, Chi‐Ling; Kuo, Stephanie Fang–Tzu; Liu, Chen–Hua; Chen, Pei‐Jer; Chen, Ding‐Shinn; Kao, Jia‐Horng

doi:10.1053/j.gastro.2012.02.007

Cited by 496 publications

(487 citation statements)

References 39 publications

Supporting

Mentioning

461

Contrasting

Unclassified

Order By: Relevance

“…The ERADICATE-B study assessed HBsAg level and risk of HCC in 2688 Taiwanese HBsAg-positive patients followed over a mean period of 14.7 yr (Tseng et al 2012). The cohort was predominantly male (61%), aged .28 yr, and genotype B (81%).…”

Section: Hccmentioning

confidence: 99%

Viral Hepatitis B: Clinical and Epidemiological Characteristics

Burns

Thompson

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Section: Hccmentioning

confidence: 99%

Viral Hepatitis B: Clinical and Epidemiological Characteristics

Burns

Thompson

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

“…Consistently, a large case-control study on Chinese CHB patients also reported that serum HBsAg \ 200 IU/mL and 0.5-log reduction in HBsAg could predict HBsAg seroclearance within 3 years [11]. In addition, in patients with low viremia (\2000 IU/mL), the higher HBsAg level ([1000 IU/ mL) is associated with the risk of disease progression, including hepatitis flares, ENH, liver cirrhosis and HCC [12,13]. In patients with low viremia (\2000 IU/mL) (Taiwanese patients with HBV genotype B or C infection), HBsAg \ 1000 IU/mL can identify a subgroup of minimal-risk HBV carriers with an annual HCC incidence of 0.06 %.…”

mentioning

confidence: 58%

Looking into the crystal ball: biomarkers for outcomes of HBV infection

Yang

Kao

2016

Hepatol Int

View full text Add to dashboard Cite

“…Regarding other viral factors, it was reported in a large Taiwanese cohort with HBV related HCC (HBeAg negative), levels of HBV surface antigen were positively correlated with incidence of HCC in those with lower levels of HBV DNA (27).…”

Section: Hbv Viral Factorsmentioning

confidence: 96%

Viral hepatitis and hepatocellular carcinoma: etiology and management

Zamor

deLemos

Russo

2017

J. Gastrointest. Oncol.

127

102

View full text Add to dashboard Cite

Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) EpidemiologyIt is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2). Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths (3). The annual incidence of HCC is estimated to be <1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. Because of worldwide and geographic variations in HBV incidence, the burden of HBV related HCC also varies. Asian-Pacific and sub-Saharan Africa represent the highest incidence of HCC worldwide. Much lower risk of HBV associated HCC is seen in the United States with less than 20% incidence. Due to its diversity, Europe has different areas: low risk (18%) in West and North and high risk (51%) East and South (4). Occult HBV or subclinical infection as defined by detectable HBV DNA in the liver but hepatitis B surface antigen (HBsAg) seronegativity is now recognized as increased risk for HCC. The risk is most notable in those over the age of 50 (5,6). Recently published data reveal that in China, the age-standardized death due to HBV-related HCC and cirrhosis in 2013 was 10.95 and 4.91 per 100,000 people (7). Fifty-five percent of all HCC cases worldwide are reported from China (8).In 1991, the WHO recommended the integration of the HBV vaccine into national immunization programs in countries with an HBV carrier prevalence of 8% or higher by 1995 and in all other countries by 1997 (9). The universal infant vaccination rate in sub-Saharan Africa was initially quite low at 5% in 2000 but increased to 72% by 2012. Parts of the Pacific region had the lowest immunization rates, but by 2012 had increased to the highest rates at 91%. Taiwan has an exceptionally higher This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.

show abstract

High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load

Cited by 496 publications

References 39 publications

Viral Hepatitis B: Clinical and Epidemiological Characteristics

Viral Hepatitis B: Clinical and Epidemiological Characteristics

Looking into the crystal ball: biomarkers for outcomes of HBV infection

Viral hepatitis and hepatocellular carcinoma: etiology and management

Contact Info

Product

Resources

About